Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 3,561 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non-small Cell Lung Cancer(NSCLC) Clear all
Completed No phase listed Observational

Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy

NCT01294280
View directory record Official record
Conditions
Lung Cancer
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 16, 2026, 9:15 AM EDT
Recruiting Phase 2 Interventional

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

NCT05657873
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, NSCLC, NSCLC Stage IV
Interventions
L-SABR, Anti-PD-(L)1 based immunotherapy, Platinum based chemotherapy
Radiation · Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 16, 2026, 9:15 AM EDT
Completed Phase 3 Interventional

Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00017459
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, tirapazamine, vinorelbine tartrate
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
42
States / cities
Los Angeles, California • Oakland, California • Orange, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 16, 2026, 9:15 AM EDT
Withdrawn Phase 2 Interventional

Non-Viral TCR Gene Therapy

NCT04102436
View directory record Official record
Conditions
Endocrine/Neuroendocrine, Non-Small Cell Lung Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancers, Ovarian Cancer
Interventions
Fludarabine, Cyclophosphamide, Aldesleukin, Sleeping Beauty Transposed PBL
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 16, 2026, 9:15 AM EDT
Completed Phase 1 Interventional

A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer

NCT06863233
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Interventions
Zirconium Zr 89 crefmirlimab berdoxam, PET/CT Scan
Drug · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 16, 2026, 9:15 AM EDT
Completed Not applicable Interventional

Palliative Care Intervention in Improving Symptom Control and Quality of Life in Patients With Stage II-IV Non-small Cell Lung Cancer and Their Family Caregivers

NCT02243748
View directory record Official record
Conditions
Caregiver, Psychological Impact of Cancer and Its Treatment, Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
Palliative Therapy, quality-of-life assessment, questionnaire administration
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Duarte, California • Irvine, California • Ontario, California + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 16, 2026, 9:15 AM EDT
Completed Phase 1 Interventional

A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma

NCT01051934
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Adenocarcinoma
Interventions
SS1 (dsFv) PE38, Paclitaxel, Carboplatin, Bevacizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 16, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

NCT02681549
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Brain Metastasis
Interventions
Pembrolizumab plus Bevacizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
New Haven, Connecticut • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 16, 2026, 9:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

NCT06088771
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Dupilumab, Cemiplimab
Biological
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 16, 2026, 9:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Cancer Associated Thrombosis and Isoquercetin (CATIQ)

NCT02195232
View directory record Official record
Conditions
Thromboembolism of Vein VTE in Colorectal Cancer, Thromboembolism of Vein in Pancreatic Cancer, Thromboembolism of Vein in Non-small Cell Lung Cancer
Interventions
Isoquercetin
Drug
Lead sponsor
Jeffrey Zwicker, MD
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Sacramento, California • West Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 16, 2026, 9:15 AM EDT
Terminated Phase 1 Interventional

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT02206763
View directory record Official record
Conditions
EGFR Mutated EGFR TKI Naive Metastatic NSCLC
Interventions
Momelotinib (MMB), Erlotinib
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Duarte, California • Palo Alto, California • Whittier, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 16, 2026, 9:15 AM EDT
Recruiting Phase 2 Interventional

Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax

NCT06262321
View directory record Official record
Conditions
Stage 4 NSCLC, Radiotherapy
Interventions
Prophylactic Palliative Radiotherapy
Radiation
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 16, 2026, 9:15 AM EDT
Completed Not applicable Interventional Results available

Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer

NCT00675597
View directory record Official record
Conditions
Lung Cancer
Interventions
Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 16, 2026, 9:15 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

NCT03425643
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pembrolizumab, Placebo, Cisplatin, Gemcitabine, Pemetrexed
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
51
States / cities
Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 16, 2026, 9:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

NCT04585815
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Sasanlimab Prefilled syringe, Encorafenib, Binimetinib, Sasanlimab, Axitinib, SEA-TGT
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
43
States / cities
Duarte, California • Encinitas, California • Fresno, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 16, 2026, 9:15 AM EDT
Active, not recruiting Phase 2 Interventional

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

NCT04268550
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Selpercatinib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
306
States / cities
Fairbanks, Alaska • Little Rock, Arkansas • Anaheim, California + 251 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 16, 2026, 9:15 AM EDT
Recruiting Phase 2 Interventional

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

NCT06731413
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, NSCLC, Advanced Non-Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Interventions
Reduced Dose of Chemotherapy and Immunotherapy
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
2
States / cities
Richmond, Virginia • Tappahannock, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 16, 2026, 9:15 AM EDT
Completed Phase 1 Interventional

Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer

NCT05712889
View directory record Official record
Conditions
Neoplasms
Interventions
VIP236 (Q3W), VIP236 (Q2W)
Drug
Lead sponsor
Vincerx Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 16, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC

NCT00343291
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Cetuximab, Bevacizumab, Paclitaxel, Carboplatin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
43
States / cities
Decatur, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Oct 16, 2026, 9:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

NCT02431260
View directory record Official record
Conditions
Solid Tumors and Hematologic Malignancy
Interventions
INCB054329 Monotherapy
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 16, 2026, 9:15 AM EDT
Completed No phase listed Observational

Hormone Changes in Women With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Receiving Erlotinib

NCT00602433
View directory record Official record
Conditions
Advanced Nonsmall Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Oct 16, 2026, 9:15 AM EDT
Terminated Phase 1 Interventional

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

NCT03054038
View directory record Official record
Conditions
Non-Small Cell Lung Carcinoma
Interventions
Afatinib, Necitumumab, Laboratory Biomarker Analysis
Drug · Biological · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Duarte, California • Stanford, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 16, 2026, 9:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer

NCT02963610
View directory record Official record
Conditions
Relapsed or Refractory Solid Tumors, Nonsmall Cell Lung Cancer
Interventions
Lenalidomide, Pembrolizumab
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 30, 2021 · Synced Oct 16, 2026, 9:15 AM EDT
Terminated Phase 2 Interventional Results available

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

NCT04914897
View directory record Official record
Conditions
Pleural Mesothelioma, Non-small Cell Lung Cancer
Interventions
THOR-707, Pembrolizumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 16, 2026, 9:15 AM EDT